Skip to main content

Table 1 Patients’ characteristics

From: Dosimetric feasibility of moderately hypofractionated/dose escalated radiation therapy for localised prostate cancer with intensity-modulated proton beam therapy using simultaneous integrated boost (SIB-IMPT) and impact of hydrogel prostate-rectum spacer

Variable 23 Patients
No (%)
Age at diagnosis (years)
Range (Mean ± SD) 52–79 (66.65 ± 7.36)
Prostate volume (cc) 25.73–109.35 (60.67 ± 21.18)
PSA at diagnosis (ng/ml)
Range (Mean ± SD) 5.03–34.78 (13.1 ± 8.5)
< 10 11 (47.8%)
10–20 7 (30.4%)
> 20 5 (21.7%)
Gleason score
3 + 4 10 (43.5%)
4 + 3 5 (21.7%)
 ≥ 4 + 4 8 (34.8%)
T stage
cT2b 4 (17.4%)
cT2c 14 (60.9%)
cT3a 2 (8.7%)
cT3b 1 (4.3%)
cT4 2 (8.7%)
N Stage
N0 23 (100%)
N+ 0
ADT
Yes 10 (43.5%)
No 13 (56.5%)
Hydrogel spacer
Yes 15 (65.2%)
No 8 (34.8%)
  1. PSA prostate-specific antigen, ADT androgen deprivation therapy